BiocSol
Seed Round in 2024
BiocSol focus on sustainable microbial-based crop protection.
Biotalys NV is an agricultural technology company based in Ghent, Belgium, that specializes in the research and development of biopesticides aimed at controlling pests and diseases affecting crops and harvested products. The company utilizes its proprietary Agrobody technology platform to create protein-based crop protection solutions that effectively bind to leaves, seeds, and fruits, enabling targeted delivery of active ingredients. This innovative approach combines the performance of traditional chemical pesticides with the safety profile of biological alternatives, making Biotalys' products suitable for both pre- and post-harvest applications. Founded in 2013, Biotalys is committed to providing sustainable and safe food protection solutions, positioning itself as a leader in the evolution of agricultural practices.
Aphea.Bio
Series C in 2023
Aphea.Bio focuses on developing innovative agricultural products aimed at enhancing crop health and yields. The company specializes in creating next-generation biopesticides derived from natural microorganisms, which serve as sustainable alternatives to traditional chemical pesticides facing regulatory challenges. Additionally, Aphea.Bio produces biostimulants that promote crop growth by enhancing nutrient uptake from the soil. Utilizing proprietary technologies, the company is dedicated to discovering new biocontrol and biostimulant products that help farmers sustainably manage fungal diseases, pests, and weeds, ultimately improving crop productivity and environmental health.
Aphea.Bio
Series B in 2020
Aphea.Bio focuses on developing innovative agricultural products aimed at enhancing crop health and yields. The company specializes in creating next-generation biopesticides derived from natural microorganisms, which serve as sustainable alternatives to traditional chemical pesticides facing regulatory challenges. Additionally, Aphea.Bio produces biostimulants that promote crop growth by enhancing nutrient uptake from the soil. Utilizing proprietary technologies, the company is dedicated to discovering new biocontrol and biostimulant products that help farmers sustainably manage fungal diseases, pests, and weeds, ultimately improving crop productivity and environmental health.
Animab is a biotechnology company focused on enhancing livestock health through innovative monoclonal antibody technology. By leveraging advanced research in animal science, Animab develops products that aim to improve animal welfare, reduce operational costs, and promote sustainability in livestock farming. Their proprietary antibodies are designed to mimic secretory IgA, a natural antibody found in colostrum and milk, which provides critical protection for piglets during the vulnerable post-weaning phase. These antibodies target specific intestinal pathogens while preserving the healthy microbiome, ensuring that piglets remain healthy and resilient during this crucial developmental period. Through its solutions, Animab seeks to benefit animals, producers, and consumers alike.
ViroVet is an innovative company focused on developing groundbreaking technologies to combat viral diseases in livestock, particularly through antiviral drugs targeting respiratory disease complexes and novel vaccines for swine. The livestock industry, valued at over 100 billion euros, faces significant financial losses due to viral diseases, which threaten global animal protein supplies. ViroVet aims to supply livestock producers, national governments, and international organizations with comprehensive solutions that can be used independently or alongside existing vaccines and biosecurity measures. With the growing world population and increased demand for protein, the risk of viral disease spread in densely populated livestock environments is rising. ViroVet has garnered support from key opinion leaders in livestock medicine, who recognize the potential of its products to reduce antibiotic use and transform the industry. Through its innovative approach, ViroVet addresses urgent challenges posed by endemic and epizootic viral diseases, ultimately aiming to enhance the resilience of the livestock sector.
Biotalys NV is an agricultural technology company based in Ghent, Belgium, that specializes in the research and development of biopesticides aimed at controlling pests and diseases affecting crops and harvested products. The company utilizes its proprietary Agrobody technology platform to create protein-based crop protection solutions that effectively bind to leaves, seeds, and fruits, enabling targeted delivery of active ingredients. This innovative approach combines the performance of traditional chemical pesticides with the safety profile of biological alternatives, making Biotalys' products suitable for both pre- and post-harvest applications. Founded in 2013, Biotalys is committed to providing sustainable and safe food protection solutions, positioning itself as a leader in the evolution of agricultural practices.
Okapi Sciences
Series A in 2008
Okapi Sciences NV is a Belgium-based company focused on developing antiviral therapeutics for pets and livestock. It operates a proprietary platform dedicated to creating innovative treatments for significant viral diseases, with five candidates currently in clinical or development stages. The company specializes in addressing viral infections affecting pets, particularly through its work on feline herpes and feline immunodeficiency virus. Okapi Sciences is committed to advancing its pipeline of antiviral drugs while fostering strong relationships with academic institutions to enhance its research capabilities and technological advancements in veterinary medicine.
Fugeia
Venture Round in 2008
Fugeia NV is develops ingredients and nutrition technologies. The company offers arabinoxylan-oligosaccharides (AXOS) ingredient that provides the health benefits of wholegrain wheat as part of the human diet, particularly in the prevention of lifestyle diseases, such as diabetes, obesity, cardiovascular diseases, and cancer; Prebiotic bread technology that allows to increase the level of arabinoxylan-oligosaccharides in bread; and AXOS-enriched beer technology that allows to increase the level of arabinoxylan-oligosaccharides. It develops products and technologies targeted for a range of market segments, including dairy and non-dairy beverages, ready-to-eat cereals, cookies and biscuits, and bread and pastry, as well as dietary supplements and therapeutics.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.